Abuse-Deterrent Guidance For Generics Years Away, Despite OxyContin ANDA Under Review
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA denies two Purdue citizen petitions, refusing once again to establish its requirements for ANDAs of the company’s abuse-deterrent OxyContin.